KENNETH MCCLAIN to Hematopoietic Stem Cell Transplantation
This is a "connection" page, showing publications KENNETH MCCLAIN has written about Hematopoietic Stem Cell Transplantation.
Connection Strength
0.327
-
Alemtuzumab and CXCL9 levels predict likelihood of sustained engraftment after reduced-intensity conditioning HCT. Blood Adv. 2023 07 25; 7(14):3725-3734.
Score: 0.112
-
Stem cell transplantation for children with hemophagocytic lymphohistiocytosis: results from the HLH-2004 study. Blood Adv. 2020 08 11; 4(15):3754-3766.
Score: 0.091
-
Challenges in the diagnosis of hemophagocytic lymphohistiocytosis: Recommendations from the North American Consortium for Histiocytosis (NACHO). Pediatr Blood Cancer. 2019 11; 66(11):e27929.
Score: 0.085
-
Confirmed efficacy of etoposide and dexamethasone in HLH treatment: long-term results of the cooperative HLH-2004 study. Blood. 2017 12 21; 130(25):2728-2738.
Score: 0.019
-
Histiocytic disorders: recent insights into pathophysiology and practical guidelines. Biol Blood Marrow Transplant. 2010 Jan; 16(1 Suppl):S82-9.
Score: 0.011
-
HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007 Feb; 48(2):124-31.
Score: 0.009